Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD)– EVO756 on track to report Phase 2b top-line data in chronic spontaneous urticaria (CSU) ...
Welcome to the Amprius Technologies Fourth Quarter and Full Year 2025 Earnings Conference Call. Joining us for today's presentation are the company's CEO, Tom Stepien; and CFO, Ricardo Rodriguez.
Joseph Todisco EVP and Chief Operating Officer — Elizabeth Masson-Hurlburt EVP and Chief Financial Officer — Susan Blum ...
Q4 2025 Earnings Call February 25, 2026 9:00 AM ESTCompany ParticipantsMussannah ChowdhuryOliver Quinn - President, CEO ...
Northwest Natural Holding Company (NYSE:NWN) Q4 2025 Earnings Call Transcript February 27, 2026 Northwest Natural Holding Company beats earnings expectations. Reported EPS is $1.39, expectations were ...
Profound Medical (NASDAQ:PROF) reported fourth-quarter 2025 revenue of $6.0 million, including $2.3 million in recurring ...
For discussion purposes, our comments on growth rates are expressed in constant currency. Dave will then return with closing ...
TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- DPM Metals Inc. (TSX: DPM, ASX: DPM) (ARBN: 689370894) (“DPM” or the “Company”) announced its operating and financial results for the fourth quarter and full ...
Certain statements made in this press release and in other written or oral statements made by Lincoln or on Lincoln’s behalf are “forward-looking statements” within the meaning of the Private ...
FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of ...
The page showcases team members sharing their personal experiences working at one of the fastest-expanding financial services companies in North America. We’re proud of our growth, but even more proud ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results